Corpus overview


Overview

MeSH Disease

Human Phenotype

Hyposmia (17)

Anosmia (11)

Fever (4)

Cough (4)

Headache (2)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 17
    records per page




    Recent smell loss is the best predictor of COVID-19: a preregistered, cross-sectional study

    Authors: Richard C. Gerkin; Kathrin Ohla; Maria Geraldine Veldhuizen; Paule V. Joseph; Christine E. Kelly; Alyssa J. Bakke; Kimberley E. Steele; Michael C. Farruggia; Robert Pellegrino; Marta Y. Pepino; Cédric Bouysset; Graciela M. Soler; Veronica Pereda-Loth; Michele Dibattista; Keiland W. Cooper; Ilja Croijmans; Antonella Di Pizio; M. Hakan Ozdener; Alexander W. Fjaeldstad; Cailu Lin; Mari A. Sandell; Preet B. Singh; V. Evelyn Brindha; Shannon B. Olsson; Luis R. Saraiva; Gaurav Ahuja; Mohammed K. Alwashahi; Surabhi Bhutani; Anna D'Errico; Marco A. Fornazieri; Jérôme Golebiowski; Liang-Dar Hwang; Lina Öztürk; Eugeni Roura; Sara Spinelli; Katherine L. Whitcroft; Farhoud Faraji; Florian Ph.S Fischmeister; Thomas Heinbockel; Julien W. Hsieh; Caroline Huart; Iordanis Konstantinidis; Anna Menini; Gabriella Morini; Jonas K. Olofsson; Carl M. Philpott; Denis Pierron; Vonnie D. C. Shields; Vera V. Voznessenskaya; Javier Albayay; Aytug Altundag; Moustafa Bensafi; María Adelaida Bock; Orietta Calcinoni; William Fredborg; Christophe Laudamiel; Juyun Lim; Johan N. Lundström; Alberto Macchi; Pablo Meyer; Shima T. Moein; Enrique Santamaría; Debarka Sengupta; Paloma Paloma Domínguez; Hüseyin Yanık; Sanne Boesveldt; Jasper H. B. de Groot; Caterina Dinnella; Jessica Freiherr; Tatiana Laktionova; Sajidxa Mariño; Erminio Monteleone; Alexia Nunez-Parra; Olagunju Abdulrahman; Marina Ritchie; Thierry Thomas-Danguin; Julie Walsh-Messinger; Rashid Al Abri; Rafieh Alizadeh; Emmanuelle Bignon; Elena Cantone; Maria Paola Cecchini; Jingguo Chen; Maria Dolors Guàrdia; Kara C. Hoover; Noam Karni; Marta Navarro; Alissa A. Nolden; Patricia Portillo Mazal; Nicholas R. Rowan; Atiye Sarabi-Jamab; Nicholas S. Archer; Ben Chen; Elizabeth A. Di Valerio; Emma L. Feeney; Johannes Frasnelli; Mackenzie Hannum; Claire Hopkins; Hadar Klein; Coralie Mignot; Carla Mucignat; Yuping Ning; Elif E. Ozturk; Mei Peng; Ozlem Saatci; Elizabeth A. Sell; Carol H. Yan; Raul Alfaro; Cinzia Cecchetto; Gérard Coureaud; Riley D. Herriman; Jeb M. Justice; Pavan Kumar Kaushik; Sachiko Koyama; Jonathan B. Overdevest; Nicola Pirastu; Vicente A. Ramirez; S. Craig Roberts; Barry C. Smith; Hongyuan Cao; Hong Wang; Patrick Balungwe; Marius Baguma; Thomas Hummel; John E. Hayes; Danielle R. Reed; Masha Y. Niv; Steven D. Munger; Valentina Parma

    doi:10.1101/2020.07.22.20157263 Date: 2020-07-26 Source: medRxiv

    Background: COVID-19 has heterogeneous manifestations, though one of the most common symptoms is a sudden loss of smell ( anosmia HP or hyposmia HP). We investigated whether olfactory loss is a reliable predictor of COVID-19. Methods: This preregistered, cross-sectional study used a crowdsourced questionnaire in 23 languages to assess symptoms in individuals self-reporting recent respiratory illness. We quantified changes in chemosensory abilities during the course of the respiratory illness using 0-100 visual analog scales (VAS) for participants reporting a positive (C19+; n=4148) or negative (C19-; n=546) COVID-19 laboratory test outcome. Logistic regression models identified singular and cumulative predictors of COVID-19 status and post-COVID-19 olfactory recovery. Results: Both C19+ and C19- groups exhibited smell loss, but it was significantly larger in C19+ participants (mean{+/-}SD, C19+: -82.5{+/-}27.2 points; C19-: -59.8{+/-}37.7). Smell loss during illness was the best predictor of COVID-19 in both single and cumulative feature models (ROC AUC=0.72), with additional features providing no significant model improvement. VAS ratings of smell loss were more predictive than binary chemosensory yes/no-questions or other cardinal symptoms, such as fever MESHD fever HP or cough MESHD cough HP. Olfactory recovery within 40 days was reported for ~50% of participants and was best predicted by time since illness onset. Conclusions: As smell loss is the best predictor of COVID-19, we developed the ODoR-19 tool, a 0-10 scale to screen for recent olfactory loss. Numeric ratings [≤]2 indicate high odds of symptomatic COVID-19 (10

    Similarities between the neurological symptoms of COVID-19 and Functional Neurological Disorder: A systematic overview of systematic reviews and implications for future neurological healthcare services

    Authors: Tamar Wildwing; Nicole Holt

    doi:10.1101/2020.07.21.20158816 Date: 2020-07-25 Source: medRxiv

    Background COVID-19, a novel coronavirus, spread rapidly across the world from December 2019. While the main symptoms of the disease MESHD are respiratory, extensive research has realised evidence of a variety of neurological symptoms, both catastrophic such as cerebrovascular disease MESHD and benign such as hyposmia HP (loss of smell). Aim To provide health professionals with better accessibility to available evidence, this paper summarises findings from a systematic overview of systematic reviews of the neurological symptoms seen in patients with COVID-19. Similarities between the neurological symptoms of COVID-19 and Functional Neurological Disorder (FND) were explored and the impact of this on neurological services and health professionals' perceptions towards FND. Methods This research was completed in three phases: phase one, a systematic overview of current reviews of neurological symptoms of COVID-19 was conducted; phase two, the most common symptoms of FND defined within key sources were collated; phase three, the neurological symptoms of COVID-19 and those of FND were compared. Results Fourteen systematic reviews were identified within seven databases, published between 1st December 2019 and 15th June 2020. The results indicated (so far), that when compared, COVID-19 and FND exhibit many similar neurological symptoms. Conclusions This led to a consideration of the implications for neurological healthcare services in the UK, and the possible change-effect on perceptions of FND. Implications may include longer waiting times and a need for more resources (including more qualified health professionals). Future research is required to explore how health professionals' perceptions of neurological symptoms may change because of COVID-19.

    Employing a Systematic Approach to Biobanking and Analyzing Genetic and Clinical Data for Advancing COVID-19 Research

    Authors: Sergio Daga; Chiara Fallerini; Margherita Baldassarri; Francesca Fava; Floriana Valentino; Gabriella Doddato; Elisa Benetti; Simone Furini; Annarita Giliberti; Rossella Tita; Sara Amitrano; Mirella Bruttini; Ilaria Meloni; Anna Maria Pinto; Francesco Raimondi; Alessandra Stella; Filippo Biscarini; Nicola Picchiotti; Marco Gori; Pietro Pinoli; Stefano Ceri; Maurizio Sanarico; Francis P. Crawley; - GEN-COVID Multicenter Study; Alessandra Renieri; Francesca Mari; Elisa Frullanti

    doi:10.1101/2020.07.24.20161307 Date: 2020-07-24 Source: medRxiv

    Within the GEN-COVID Multicenter Study, biospecimens from more than 1,000 SARS-CoV-2-positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum SERO, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O2 supplementation, and without respiratory support (9.5%, 18.4%, 31.55% and 14.8, respectively); and non-hospitalized subjects (25.75%), either pauci- or asymptomatic TRANS. More than 150 clinical patient-level data fields have been collected and binarized according to the organs/systems primarily affected by COVID-19: heart, liver, pancreas, kidney, chemosensors, innate or adaptive immunity, and clotting system, for further statistics. Hierarchical Clustering analysis identified five main clinical categories: i) severe multisystemic failure with either thromboembolic or pancreatic variant; ii) cytokine storm type either severe with liver involvement or moderate; iii) moderate heart type either with or without liver damage; iv) moderate multisystemic involvement either with or without liver damage; v) mild either with or without hyposmia HP. GCB and GCPR are further linked to the GEN-COVID Genetic Data Repository (GCGDR), which includes data from Whole Exome Sequencing and high-density SNP genotyping. The data are available for sharing through the Network for Italian Genomes, within the COVID-19 dedicated section. The study objective is to systematize this comprehensive data collection and start identifying multi-organ involvement in COVID-19, defining genetic parameters for infection MESHD susceptibility within the population, and mapping genetically COVID-19 severity and clinical complexity among patients.

    Olfactory and gustatory dysfunction in 2019 novel coronavirus: An updated systematic review and meta-analysis

    Authors: Marzieh Esmaeili; Fatemeh Abdi; Gita Shafiee; Hadis Rastad; Hamid Asayesh; Zahra Esmaeili Abdar; Fereshteh Baygi; Mostafa Qorbani

    doi:10.21203/rs.3.rs-44648/v1 Date: 2020-07-17 Source: ResearchSquare

    BackgroundEvidence showed that partial or complete loss of smell and taste might be a possible primary symptom of the 2019 novel coronavirus (COVID-19). This study aimed to systematically review and pool all available evidence on the olfactory and gustatory dysfunction in COVID-19 patients. MethodsIn this systematic review, a comprehensive search was carried out systematically through e-databases including PubMed, EMBASE, Scopus, and Web of Science (WoS); that was limited to English-language studies published from 2019 up to 6th May 2020. Afterward, all studies reported the taste and smell dysfunction in the COVID-19 patients were included. The quality of the studies was assessed by the Mixed Methods Appraisal Tool (MMAT). The pooled prevalence SERO of olfactory and gustatory dysfunction was estimated using the random effects meta-analysis method.ResultsAmong 28 eligible included studies in this systematic review, finally, 22 studies met the eligibility criteria and were included in the meta-analysis. According to the random effect meta-analysis, the global pooled prevalence SERO (95% confidence interval) of any olfactory dysfunction, anosmia HP, and hyposmia HP was 55% (40%-70%), 40% (22%-57%), and 40% (20%-61%) respectively. The pooled estimated prevalence SERO of any gustatory dysfunction, ageusia MESHD, and dysgeusia MESHD was 41% (23%-59%), 31% (3%-59%), and 34% (19%-48%) respectively. ConclusionOlfactory and gustatory dysfunction is prevalent among COVID-19 patients. Therefore, olfactory and gustatory dysfunction seems to be part of important symptoms and notify for the diagnosis of COVID-19, especially in the early phase of the infection MESHD.

    Prevalence SERO and Recovery of Olfactory Dysfunction in 1,363 patients with coronavirus disease MESHD 2019: A Multicenter Longitudinal Study.

    Authors: Jerome Lechien; Carlos Chiesa-Estomba; Eline Beckers; Vincent Mustin; Morgane Ducarme; Fabrice Journe; Arnaud Marchant; Lionel Jouffe; Maria Barillari; Stephane Hans; Sven Saussez

    doi:10.21203/rs.3.rs-38504/v1 Date: 2020-06-29 Source: ResearchSquare

    Olfactory dysfunction (OD) is a key symptom of coronavirus disease MESHD 2019 (COVID-19). Currently, a few data are available about the recovery of OD after the infection MESHD resolution. In this study, we investigated both prevalence SERO and recovery rate of OD with subjective and objective clinical tools in 2,581 patients. First, our data showed that the prevalence SERO of OD was significantly higher in mild form (85.9%) compared with moderate-to-critical forms (4.5-9.7%; p=0.001). Second, focusing on patients with OD who completed the 2-month follow-up period (N=1,363), we observed that 328 patients (24.1%) did not subjectively recover olfaction 60 days after the onset of the dysfunction. The mean duration of self-reported OD was 21.6±17.9 days. Third, the objective olfactory evaluations performed on a subset of patients (N=233) reported hyposmia HP or anosmia HP in 54.7% and 36.6% of mild and moderate-to-critical forms, respectively (p=0.001). At the end of follow-up, 15.3% of anosmic/hyposmic patients did not objectively recover olfaction. The higher baseline severity of objective olfactory evaluations was strongly predictive of persistent OD (p<0.001). OD disappeared in 75% to 85% of patients regarding self-reported or objective olfactory evaluations.

    Standardized Testing Demonstrates Altered Odor Detection Sensitivity SERO and Hedonics in Asymptomatic TRANS College Students as SARS-CoV-2 Emerged Locally

    Authors: Julie Walsh-Messinger; Sahar Kaouk; Hannah Manis; Rachel Kaye; Guillermo Cecchi; Pablo Meyer; Dolores Malaspina

    doi:10.1101/2020.06.17.20106302 Date: 2020-06-19 Source: medRxiv

    Background Anosmia HP is a recognized symptom of COVID-19, but the relationship of SARS-CoV-2 exposure with olfactory dysfunction remains enigmatic. This report adds unique data from healthy students tested as the virus emerged locally. Methods Psychometrically validated measures assessed odor detection, identification and hedonics in healthy university students. Data from asymptomatic TRANS students (N=22), tested as SARS-CoV-2 unknowingly emerged locally, were compared to students tested just prior to local virus transmission TRANS (N=25), and our normative sample (N=272) tested over the previous 4 years. Results The exposed cohort demonstrated significantly reduced odor detection sensitivity SERO compared to the students in the prior group (P=.01; d=0.77; CI 0.17, 1.36), with a distribution skewed towards less detection sensitivity SERO (P=.03). Categorically, the exposed group was significantly more likely to have hyposmia HP (OR=7.7; CI, 3.1, 19.4), particularly the subset assessed in the final week before campus closure (OR=13.6; CI, 3.4, 35.7). The exposed group also rated odors as less unpleasant (P

    Sudden Onset, Acute Loss of Taste and Smell in Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review

    Authors: Lakshman SAMARANAYAKE; Kausar Fakhruddin; Chamila Panduwawala

    id:10.20944/preprints202006.0198.v1 Date: 2020-06-16 Source: Preprints.org

    Early detection, isolation, and management of COVID-19 patients are crucial to contain the current pandemic. The CDC in USA recently included "sudden loss of taste ( dysgeusia MESHD/ ageusia MESHD) and smell ( anosmia HP/ hyposmia HP)” as symptoms of COVID-19. If these symptoms are reliable forerunner symptoms of COVID-19, then it may facilitate early detection and containment of the disease MESHD. Hence, we systematically evaluated the contemporary evidence on dysgeusia MESHD and anosmia HP as trigger symptoms in COVID-19. Ovid MEDLINE, EBSCO host, and Web of Science databases were searched between December 25, 2019-May 30, 2020.Of the 13 identified records, eight (totaling 11,054 COVID-19 patients), were included, as per the selection criteria. The studies emanated mostly from the European community, as well as China, the USA, and Iran. In total, anosmia HP and dysgeusia MESHD symptoms were present in 74.9 % and 81.3% ambulatory as well as hospitalized, mild-to-severe cases of COVID-19 patients, respectively. The European, US, and Iran data indicate that olfactory, and gustatory symptoms appear prior to general COVID-19 symptoms in a majority of the patients. To our knowledge, this is the first systematic review analyzing the prevalence SERO of chemosensory dysfunction in COVID-19. Further, studies are essential to evaluate their utility as harbingers of COVID-19 onset, and to establish clinical practice guidelines.

    Olfactory dysfunction quantified by olfactometry in patients with SARS-Cov-2 infection MESHD

    Authors: Maria Teresa Cervilla; Irene Gutierrez; Maria Romero; Javier Garcia-Gomez

    doi:10.21203/rs.3.rs-35796/v1 Date: 2020-06-15 Source: ResearchSquare

    Objective: To quantify olfactory dysfunction by olfactometry in patients with laboratory confirmed SARS-Cov-2 infection MESHD.Methods: Patients from a particular Spanish health area with SARS-Cov-2 infection MESHD were recruited to study the loss of smell. Olfactometry was performed using the Sniffin Sticks test. The following clinical symtoms were studied: ENT symptoms related to infection MESHD, duration of sensorineural loss, subjective and objective score of loss of smell, and its temporal relationship with other systemic symptoms.Results: A total of 51 patients with SARS-Cov-2 infection MESHD completed the study. A total of 86.3% reported subjective loss of smell capacity. Objective loss of olfactory ability was quantified by olfactometry in 22% of patients. Statistical significance was demonstrated between the group of patients with anosmia HP/ hyposmia HP and the Sniffin Sticks test (p-value: 0.013). The most frequent ENT symptoms in patients with quantified olfactory loss consisted of nasal obstruction MESHD nasal obstruction HP, absence of rhinorrhea HP, sore throat, and ear pain HP pain MESHD. The subjective olfactory recovery rate prior to performing olfactometry was 64.3% of the sample. A total of 77% of patients in whom olfactory loss was quantified by olfactometry reported a subjective duration of more than 15 days.Conclusion: Olfactory dysfunction is an objective clinical finding in patients with SARS- Cov-2 infection MESHD. Its persistence has been demonstrated beyond the first month after infection MESHD. Their quantitative study should be continued to determine the recovery rate and its possible long-term sequelae, as well as treatments to improve the quality of life of these patients.

    Clinical and molecular characterization of COVID-19 hospitalized patients

    Authors: Elisa Benetti; Annarita Giliberti; Arianna Emiliozzi; Floriana Velentino; Laura Bergantini; Chiara Fallerini; Federico Anedda; Sara Amitrano; Edoardo Conticini; Rossella Tita; Miriana DAlessandro; Francesca Fava; Simona Marcantonio; Margherita Baldassarri; Mirella Bruttini; Maria Antonietta Mazzei; Francesca Montagnani; Marco Mandala; Elena Bargagli; Simone Furini; - COVID-19 MULTICENTER STUDY; Alessandra Renieri; Francesca Mari

    doi:10.1101/2020.05.22.20108845 Date: 2020-05-25 Source: medRxiv

    Clinical and molecular characterization by Whole Exome Sequencing (WES) is reported in 35 COVID-19 patients attending the University Hospital in Siena, Italy, from April 7 to May 7, 2020. Eighty percent of patients required respiratory assistance, half of them being on mechanical ventilation. Fiftyone percent had hepatic involvement and hyposmia HP was ascertained in 3 patients. Searching for common genes by collapsing methods against 150 WES of controls of the Italian population failed to give straightforward statistically significant results with the exception of two genes. This result is not unexpected since we are facing the most challenging common disorder triggered by environmental factors with a strong underlying heritability (50%). The lesson learned from Autism HP-Spectrum-Disorders prompted us to re-analyse the cohort treating each patient as an independent case, following a Mendelian-like model. We identified for each patient an average of 2.5 pathogenic mutations involved in virus infection MESHD susceptibility and pinpointing to one or more rare disorder(s). To our knowledge, this is the first report on WES and COVID-19. Our results suggest a combined model for COVID-19 susceptibility with a number of common susceptibility genes which represent the favorite background in which additional host private mutations may determine disease progression MESHD.

    Psychophysical Olfactory Findings of Mild-to-moderate COVID-19 Patients: Preliminary Report.

    Authors: Jerome R. Lechien; sven saussez; Pierre Cabaraux; Stephane Hans; Mohamad Khalife; Delphine Martiny; Carlos Chiesa

    doi:10.1101/2020.05.02.20070581 Date: 2020-05-06 Source: medRxiv

    Since the onset of the COVID-19 infection MESHD, many patients reported sudden loss of smell (SLS). However, due to the lack of psychophysical testings, it remains difficult to know if these patients really have hyposmia HP or anosmia HP. Our group investigated the prevalence SERO of anosmia HP and hyposmia HP in 28 COVID-19 patients and the potential association with nasal complaints.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.